This inventor holds 2 USPTO granted patents. Top assignee: Council of Scientific and Industrial Research. Active years: 2014-2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Pune, IN (2014)
- Maharashtra, IN (2016)
Company Filing History:
Years Active: 2014-2016
Title: Arshad Khan: Innovator in Anti-Tubercular Compounds
Introduction
Arshad Khan is a notable inventor based in Maharashtra, India. He has made significant contributions to the field of medicinal chemistry, particularly in the development of anti-tubercular compounds. With a total of 2 patents, his work focuses on innovative solutions to combat tuberculosis.
Latest Patents
Arshad Khan's latest patents include the invention of 1, 2, 4-triazole derivatives and their anti-microbial activity. This invention details triazole derivatives that are useful as anti-tubercular compounds, along with a process for their preparation. Additionally, he has developed a method for inhibiting the growth of BCG and H37Ra using these triazoles. Another significant patent involves 1, 2, 4-triazole derivatives and their anti-mycobacterial activity, which provides antitubercular compounds selected from propargylated 1,2,3 triazoles of specific formulas.
Career Highlights
Arshad Khan is affiliated with the Council of Scientific and Industrial Research, where he conducts his research and development activities. His work has been instrumental in advancing the understanding and treatment of tuberculosis through innovative chemical compounds.
Collaborations
Some of his notable coworkers include Shailaja Pramod Maybhate and Preeti Madhukar Chaudhary. Their collaborative efforts contribute to the success of the projects undertaken at the Council of Scientific and Industrial Research.
Conclusion
Arshad Khan's contributions to the field of anti-tubercular compounds highlight his innovative spirit and dedication to addressing critical health challenges. His patents reflect a commitment to scientific advancement and the potential to improve treatment options for tuberculosis.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
